세계의 카르티노이드 종양 시장 보고서(2025년)

A carcinoid tumor is a rare, slow-growing neuroendocrine tumor that typically develops in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms vary depending on the tumor's location and whether it secretes hormones, potentially leading to carcinoid syndrome.

The primary types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) arise from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatment options include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral and parenteral routes. These treatments are distributed through both online and offline channels and are utilized by hospitals, clinics, academic institutions, and research organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The carcinoid tumor market research report is one of a series of new reports from The Business Research Company that provides carcinoid tumor market statistics, including the carcinoid tumor industry global market size, regional shares, competitors with the carcinoid tumor market share, detailed carcinoid tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing incidence of neuroendocrine tumors, rising awareness about rare cancers, improving healthcare infrastructure, availability of targeted therapies, and expansion of clinical trials for new treatment options.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.62 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to growing demand for personalized medicine, increasing focus on early detection and diagnosis, rising adoption of minimally invasive surgeries, expanding research on novel therapies, and increasing use of molecular targeted therapies. Major trends in the forecast period include integration of AI and machine learning in diagnostics, shift toward combination therapies, telemedicine and remote monitoring, patient-centric care, collaborative research.

The forecast of 10.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. neuroendocrine cancer care by increasing costs for somatostatin analogs and Ga-68 DOTATATE imaging agents imported from Switzerland and Germany, potentially worsening treatment outcomes. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of obesity is driving the growth of the carcinoid tumor market. Obesity, characterized by a body mass index (BMI) of 30 or higher, is rising due to factors such as poor dietary habits, lack of physical activity, and excessive consumption of processed foods. This condition promotes chronic inflammation, insulin resistance, and the secretion of growth factors that contribute to tumor development, including carcinoid tumors. For example, according to the Centers for Disease Control and Prevention (CDC), in 2022, 22 U.S. states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. As obesity rates continue to rise, the incidence of obesity-related cancers, including carcinoid tumors, is expected to increase, further expanding the market.

Advancements in neuroendocrine tumor detection are also playing a crucial role in market growth. Companies are developing innovative diagnostic tools, such as fully automated chromogranin A (CgA) tests, to enhance early detection and improve treatment outcomes. In October 2023, Thermo Fisher Scientific received FDA clearance for the Thermo Scientific B*R*A*H*M*S CgA II KRYPTOR immunoassay, the first FDA-approved chromogranin A test. This fully automated test measures CgA levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping monitor tumor progression and assess treatment efficacy. By utilizing TRACE technology, the test provides precise results in under 30 minutes, replacing manual laboratory-developed tests and improving diagnostic accuracy and efficiency.

In April 2022, SERB Pharmaceuticals acquired the European commercialization rights for Xermelo (telotristat ethyl) from Ipsen. Xermelo is a treatment for carcinoid syndrome diarrhea, a symptom of carcinoid tumors. This acquisition strengthens SERB's portfolio of treatments for rare diseases and expands access to improved therapeutic options outside the U.S. and Japan. Ipsen, a France-based biopharmaceutical company, continues to focus on developing treatments for carcinoid syndrome and other rare cancers, contributing to the overall growth of the market.

Major players in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carcinoid tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carcinoid Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carcinoid tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carcinoid tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The carcinoid tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types
• 2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Online Channel; Offline Channel
• 5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations
• Subsegments:
• 1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors
• 2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma
• 3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors
• 4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Siemens Healthineers AG; Boston Scientific Corporation; Boehringer Ingelheim International GmbH; Catalent Inc; Ipsen S.A.; Exelixis Inc; Novocure Limited; Hutchison MediPharma Limited (A subsidiary of HUTCHMED); Tarveda Therapeutics Inc.; Lexicon Pharmaceuticals Inc.; Dauntless Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Carcinoid Tumor Market Characteristics

3. Carcinoid Tumor Market Trends And Strategies

4. Carcinoid Tumor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Carcinoid Tumor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Carcinoid Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Carcinoid Tumor Market Growth Rate Analysis
• 5.4. Global Carcinoid Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Carcinoid Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Carcinoid Tumor Total Addressable Market (TAM)

6. Carcinoid Tumor Market Segmentation

• 6.1. Global Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Lung Neuroendocrine Tumor
• Other Disease Types
• 6.2. Global Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Octreotide
• Lanreotide
• Telotristat ethyl
• Capecitabine (Xeloda)
• 5-Fluorouracil (5-FU)
• Doxorubicin (Adriamycin)
• Etoposide (VP-16)
• Dacarbazine (DTIC)
• Streptozocin
• Other Treatments
• 6.3. Global Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Carcinoid Tumor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Carcinoid Tumor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Clinics
• Academic Institutions
• Research Organizations
• 6.6. Global Carcinoid Tumor Market, Sub-Segmentation Of Gastrointestinal Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Bowel Neuroendocrine Tumors
• Colorectal Neuroendocrine Tumors
• Appendiceal Neuroendocrine Tumors
• 6.7. Global Carcinoid Tumor Market, Sub-Segmentation Of Pancreatic Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulinoma
• Non-insulinoma
• Glucagonoma
• 6.8. Global Carcinoid Tumor Market, Sub-Segmentation Of Lung Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Typical Carcinoid Tumors
• Atypical Carcinoid Tumors
• 6.9. Global Carcinoid Tumor Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thymic Neuroendocrine Tumors
• Ovarian Neuroendocrine Tumors

7. Carcinoid Tumor Market Regional And Country Analysis

• 7.1. Global Carcinoid Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Carcinoid Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carcinoid Tumor Market

• 8.1. Asia-Pacific Carcinoid Tumor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carcinoid Tumor Market

• 9.1. China Carcinoid Tumor Market Overview
• 9.2. China Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carcinoid Tumor Market

• 10.1. India Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carcinoid Tumor Market

• 11.1. Japan Carcinoid Tumor Market Overview
• 11.2. Japan Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carcinoid Tumor Market

• 12.1. Australia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carcinoid Tumor Market

• 13.1. Indonesia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carcinoid Tumor Market

• 14.1. South Korea Carcinoid Tumor Market Overview
• 14.2. South Korea Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carcinoid Tumor Market

• 15.1. Western Europe Carcinoid Tumor Market Overview
• 15.2. Western Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carcinoid Tumor Market

• 16.1. UK Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carcinoid Tumor Market

• 17.1. Germany Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carcinoid Tumor Market

• 18.1. France Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carcinoid Tumor Market

• 19.1. Italy Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carcinoid Tumor Market

• 20.1. Spain Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carcinoid Tumor Market

• 21.1. Eastern Europe Carcinoid Tumor Market Overview
• 21.2. Eastern Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carcinoid Tumor Market

• 22.1. Russia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carcinoid Tumor Market

• 23.1. North America Carcinoid Tumor Market Overview
• 23.2. North America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carcinoid Tumor Market

• 24.1. USA Carcinoid Tumor Market Overview
• 24.2. USA Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carcinoid Tumor Market

• 25.1. Canada Carcinoid Tumor Market Overview
• 25.2. Canada Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carcinoid Tumor Market

• 26.1. South America Carcinoid Tumor Market Overview
• 26.2. South America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carcinoid Tumor Market

• 27.1. Brazil Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carcinoid Tumor Market

• 28.1. Middle East Carcinoid Tumor Market Overview
• 28.2. Middle East Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carcinoid Tumor Market

• 29.1. Africa Carcinoid Tumor Market Overview
• 29.2. Africa Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carcinoid Tumor Market Competitive Landscape And Company Profiles

• 30.1. Carcinoid Tumor Market Competitive Landscape
• 30.2. Carcinoid Tumor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Carcinoid Tumor Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Siemens Healthineers AG
• 31.6. Boston Scientific Corporation
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Catalent Inc
• 31.9. Ipsen S.A.
• 31.10. Exelixis Inc
• 31.11. Novocure Limited
• 31.12. Hutchison MediPharma Limited (A subsidiary of HUTCHMED)
• 31.13. Tarveda Therapeutics Inc.
• 31.14. Lexicon Pharmaceuticals Inc.
• 31.15. Dauntless Pharmaceuticals Inc.

32. Global Carcinoid Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carcinoid Tumor Market

34. Recent Developments In The Carcinoid Tumor Market

35. Carcinoid Tumor Market High Potential Countries, Segments and Strategies

• 35.1 Carcinoid Tumor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Carcinoid Tumor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Carcinoid Tumor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer